Central tolerance to myogenic cell transplants does not include muscle neoantigens

Transplantation

Volumn 85, Issue 12, 2008, Pages 1791-1801

  Camirand, Geoffrey ^a   Stéphan, Lionel ^b   Rousseau, Joël ^b   Sackett, Mélanie K ^b   Caron, Nicolas J ^b   Mills, Philippe ^b   Kurtz, Josef ^c   Sykes, Megan ^c   Rothstein, David M ^a   Tremblay, Jacques P ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LAVAL UNIVERSITY   (Canada)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Dystrophin; Foxp3; Tolerance; Transplantation

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; DYSTROPHIN; OKT 8; PERFORIN; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3; ANTIGEN; CD40 LIGAND; CD8 ANTIGEN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; EFFECTOR CELL; GRAFT REJECTION; GRAFT SURVIVAL; HLA MATCHING; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTIC INFILTRATION; MOUSE; MYELOABLATIVE CONDITIONING; NEWBORN; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PHENOTYPE; PRIORITY JOURNAL; RADIATION CHIMERA; RADIATION DOSE; REGULATORY T LYMPHOCYTE; SKIN ALLOGRAFT; SKIN GRAFT REJECTION; SKIN TRANSPLANTATION; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION TOLERANCE; WHOLE BODY RADIATION; ANIMAL; ANIMAL MUSCULAR DYSTROPHY; BAGG ALBINO MOUSE; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL TRANSPLANTATION; CHIMERA; COMPARATIVE STUDY; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; PATHOLOGY; RADIATION EXPOSURE; SKELETAL MUSCLE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; ANTIGENS; ANTIGENS, CD8; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; CELL TRANSPLANTATION; CHIMERA; DISEASE MODELS, ANIMAL; DYSTROPHIN; IMMUNE TOLERANCE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; SKIN TRANSPLANTATION; WHOLE-BODY IRRADIATION;

EID: 49149104921     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31817726bc     Document Type: Article

References (52)

1. Bonilla E, Samitt CE, Miranda AF, et al. Duchenne muscular dystrophy: Deficiency of dystrophin at the muscle cell surface. Cell 1988; 54: 447.
2. Nowak KJ, Davies KE. Duchenne muscular dystrophy and dystrophin: Pathogenesis and opportunities for treatment. EMBO Rep 2004; 5: 872.
3. Partridge TA, Morgan JE, Coulton GR, et al. Conversion of mdx myofibres from dystrophin-negative to positive by injection of normal myoblasts. Nature 1989; 337: 176.
4. Skuk D, Goulet M, Roy B, et al. Myoblast transplantation in whole muscle ofnonhuman primates.J Neuropathol Exp Neurol 2000; 59: 197.
5. Skuk D, Goulet M, Roy B, et al. First test of a "high-density injection" protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: Eighteen months follow-up. Neuromuscul Disord 2007; 17: 38.
6. Brussee V, Merly F, Tardif F, et al. Normal myoblast implantation in MDX mice prevents muscle damage by exercise. Biochem Biophys Res Commun 1998; 250: 321.
7. Alameddine HS, Louboutin JP, Dehaupas M, et al. Functional recovery induced by satellite cell grafts in irreversibly injured muscles. Cell Transplant 1994; 3: 3.
8. Irintchev A, Langer M, Zweyer M, et al. Functional improvement of damaged adult mouse muscle by implantation of primary myoblasts. J Physiol 1997; 500(Pt 3): 775.
9. Ohtsuka Y, Udaka K, Yamashiro Y, et al. Dystrophin acts as a transplantation rejection antigen in dystrophin-deficient mice: Implication for gene therapy. J Immunol 1998; 160: 4635.
10. Gilchrist SC, Ontell MP, Kochanek S, et al. Immune response to full-length dystrophin delivered to Dmd muscle by a high-capacity adenoviral vector. Mol Ther 2002; 6: 359.
11. Vilquin JT, Wagner E, Kinoshita I, et al. Successful histocompatible myoblast transplantation in dystrophin- deficient mdx mouse despite the production of antibodies against dystrophin. J Cell Biol 1995; 131: 975.
12. Huard J, Bouchard JP, Roy R, et al. Human myoblast transplantation: Preliminary results of 4 cases. Muscle Nerve 1992; 15: 550.
13. Tremblay JP, Malouin F, Roy R, et al. Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. Cell Transplant 1993; 2: 99.
14. Kinoshita I, Roy R, Dugre FJ, et al. Myoblast transplantation in monkeys: Control of immune response by FK506. J Neuropathol Exp Neurol 1996; 55: 687.
15. CamirandG,Caron NJ, Turgeon NA,et al. Treatment with anti-CD154 antibody and donor-specific transfusion prevents acute rejection of myoblast transplantation. Transplantation 2002; 73: 453.
16. Larsen CP, Alexander DZ, Hollenbaugh D, et al. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejectionbyblockade of the CD40-gp39 pathway. Transplantation 1996; 61: 4.
17. Parker DC, GreinerDL, Phillips NE, et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA 1995; 92: 9560.
18. Rothstein DM, Livak MF, Kishimoto K, et al. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J Immunol 2001; 166: 322.
19. Wekerle T, Sykes M. Mixed chimerism and transplantation tolerance. Annu Rev Med 2001; 52: 353.
20. Sayegh MH, Fine NA, Smith JL, et al. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors [see comments]. Ann Intern Med 1991; 114: 954.
21. Jacobsen N, Taaning E, Ladefoged J, et al. Tolerance to an HLA-B, DR disparate kidney allograft after bone-marrow transplantation from same donor [letter]. Lancet 1994; 343: 800.
22. Svendsen UG, Aggestrup S, Heilmann C, et al. Transplantation of a lobe of lung from mother to child following previous transplantation with maternal bone marrow. J Heart Lung Transplant 1999; 18: 388.
23. Buhler LH, Spitzer TR, Sykes M, et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74: 1405.
24. Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68: 480.
25. Fudaba Y, Spitzer TR, Shaffer J, et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: In vivo and in vitro analyses. Am J Transplant 2006; 6: 2121.
26. Ito H, Kurtz J, Shaffer J, et al. CD4 T cell-mediated alloresistance to fully MHC-mismatched allogeneic bone marrow engraftment is dependent on CD40-CD40 ligand interactions, and lasting T cell tolerance is induced by bone marrow transplantation with initial blockade of this pathway. J Immunol 2001; 166: 2970.
27. Cossu G, Zani B, ColettaM, et al. In vitro differentiation of satellite cells isolated from normal and dystrophic mammalian muscles. A comparison with embryonic myogenic cells. Cell Differ 1980; 9: 357.
28. Wakeford S, Watt DJ, Partridge TA. X-irradiation improves mdx mouse muscle as a model of myofiber loss in DMD. Muscle Nerve 1991; 14: 42.
29. Camirand G, Rousseau J, Ducharme ME, et al. Novel duchenne muscular dystrophy treatment through myoblast transplantation tolerance with anti-CD45RB, anti-CD154 and mixed chimerism. Am J Transplant 2004; 4: 1255.
30. Wekerle T, Sayegh MH, Hill J, et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 1998; 187:2037.
31. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151.
32. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330.
33. Guerette B, Asselin I, Skuk D, et al. Control of inflammatory damage by anti-LFA-1: Increase success of myoblast transplantation. Cell Transplant 1997; 6: 101.
34. Guerette B, Gingras M, Wood K, et al. Immunosuppression with monoclonal antibodies and CTLA4-Ig after myoblast transplantation in mice. Transplantation 1996; 62: 962.
35. Skuk D, Caron N, Goulet M, et al. Dynamics of the early immune cellular reactions after myogenic cell transplantation. Cell Transplant 2002; 11: 671.
36. Garlepp MJ, Chen W, Tabarias H, et al. Antigen processing and presentation by a murine myoblast cell line. Clin Exp Immunol 1995; 102:614.
37. Goebels N, Michaelis D, Wekerle H, et al. Human myoblasts as antigen-presenting cells. J Immunol 1992; 149:661.
38. Vilquin JT, Asselin I, Guerette B, et al. Successful myoblast allotransplantation in mdx mice using rapamycin. Transplantation 1995; 59: 422.
39. Tomita Y, Khan A, Sykes M. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen. J Immunol 1994; 153: 1087.
40. Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the air protein. Science 2002; 298:1395.
41. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199.
42. Waldmann H, Graca L, Cobbold S, et al. Regulatory T cells and organ transplantation. Semin Immunol 2004; 16: 119.
43. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531.
44. Salvalaggio PR, Camirand G, Ariyan CE, et al. Antigen exposure during enhanced CTLA-4 expression promotes allograft tolerance in vivo. JImmunol 2006; 176:2292.
45. Lee I, Wang L, Wells AD, et al. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. JExp Med 2005; 201: 1037.
46. Nishimura E, Sakihama T, Setoguchi R, et al. Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3 + CD25 + CD4+ regulatory T cells. Int Immunol 2004; 16: 1189.
47. Walker LS, Chodos A, Eggena M, et al. Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. JExpMed 2003; 198: 249.
48. Cobbold SP, Castejon R, Adams E, et al. Induction of foxP3+ regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J Immunol 2004; 172: 6003.
49. Karim M, Kingsley CI, Bushell AR, et al. Alloantigen-induced CD25 + CD4+ regulatory T cells can develop in vivo from CD25 - CD4+ precursors in a thymus-independent process. J Immu-nol 2004; 172: 923.
50. Apostolou I, von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J Exp Med 2004; 199: 1401.
51. Fehr T, Takeuchi Y, Kurtz J, et al. Early regulation of CD8 T cell allo-reactivity by CD4( + )CD25( - )T cells in recipients of anti-CD154 antibody and allogeneic BMT is followed by rapid peripheral deletion of donor-reactive CD8( + ) T cells, precluding a role for sustained regulation. Eur J Immunol 2005; 35: 2679.
52. Kurtz J, Shaffer J, Lie A, et al. Mechanisms of early peripheral CD4 T-cell tolerance induction by anti-CD154 monoclonal antibody and allogeneic bone marrow transplantation: Evidence for anergy and deletion but not regulatory cells. Blood 2004; 103: 4336.